NNIT A/S : First six months 2023 Roadshow Presentation

Q2 2023

Webcast Presentation

August 31, 2023

Key figures Q2 2023

Revenue growth

15%

Operating profit

before special items (DKKm)

25

Organic revenue growth		Revenue (DKKm)
11%		424

Operating profit margin		Special items (DKKm)
before special items
	30
5.9%

2

New regional and financial reporting structure

•	Regional organizational structure introduced after
	divestment of infrastructure business
	• 4 regions assisted by Global Delivery & Support
•	Focus on increasing customer proximity and enhancing
	global coordination across regions
•	Unchanged focus on high complexity industries within global
	life sciences, the Danish public sector and through SCALES
•	New financial reporting structure in place in Q2
	• 4 regional P&Ls consolidated in Group P&L

Employees

• Increased transparency in respect of financial and business

335

310

520

performance for each region

160 390

Denmark	Europe
US	Asia

Global Delivery & Support	3

Region Denmark

• Well-positionedin recession-proof Danish public space, incl. central government and publicly owned companies operating on commercial terms, as well as towards private companies facing strict regulatory demands or high complexity
• • Life sciences customers in Denmark customers are served by region Europe
• Solid 22% revenue growth driven by major public wins in previous periods, high activity level and particularly strong development in Group company SCALES
• Strong earnings growth from improved capacity utilization and despite increase in production costs in Q2
• Positive market outlook and order situation with significant contract expansions

Revenue and profitability

200					20.2%	164	166	25
						20
150		136		133
										15
100							154
									13.5%	10.9%	10
												5
50		0.8%	6.5%
0													0
												-5
-50													-10
			Q2-22	Q3-22		Q4-22	Q1-23	Q2-23
					Revenue (DKKm)				Group operating profit* (%)
	DKKm				Q2-23Q1-23	Q4-22	Q3-22	Q2-22
	Revenue		166		164	154	133		136
	Production cost		-118		-109	-99	-78		-97
	Gross profit		48		55	55	55		39
	Gross profit margin	29.1%		33.5%	35.5%	41.4%		28.9%
	Regional operating profit	37		44	43	36		26
	Group operating profit	18		22	31	1		1
	Group operating profit (%)	10.9%		13.5%	20.2%	6.5%		0.8%

*Operating profit and margin before special items

Region Europe

• A leading and trusted partner for life sciences clients in Europe with activities across the entire value chain and footprint in Germany, Switzerland, UK, Ireland, Czech Republic, Poland, Italy, Spain and Denmark
• Stable Q2 revenue in market impacted by macroeconomic volatility and slower investment decision-making
• Disciplined cost management entailed reduction of production costs and improved gross profit
• Operating profit continued upwards trend and reached break-even after efficiency enhancements
• Extensions and expansions of several long-term customer engagements in life sciences and manufacturing solutions

Revenue and profitability

119 122 115 112 119

85			9
35			4
			0%	-1
-15
	-3.1%	-0.5%
-65	-5.2%	-6
-115			-11
-165		-12.7%	-16

Q2-22	Q3-22	Q4-22	Q1-23	Q2-23
		Revenue (DKKm)		Group operating profit* (%)

DKKm	Q2-23	Q1-23	Q4-22	Q3-22	Q2-22
Revenue	119	112	115	122	119
Production cost	-91	-83	-103	-88	-90
Gross profit	28	29	12	34	29
Gross profit margin	23.7%	26.0%	11.7%	27.7%	24.4%
Regional operating profit	14	17	-5	15	15
Group operating profit	0	-1	-15	-4	-6
Group operating profit (%)	0%	-0.5%	-12.7%	-3.1%	-5.2%

*Operating profit and margin before special items